Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2022 Earnings and Company Updates

Rhea-AI Summary

Intellia Therapeutics (NASDAQ:NTLA) will announce its fourth quarter and full-year 2022 financial results on February 23, 2023, at 8 a.m. ET. Investors can join the conference call by dialing 1-833-316-0545 (U.S.) or 1-412-317-5726 (international) five minutes prior. A live webcast will also be available through their website. Intellia is a leader in developing CRISPR-based genome editing therapeutics, focusing on innovative treatments for various diseases through in vivo and ex vivo programs. The company aims to unlock the full potential of genetic medicine.

Positive

• Leading position in CRISPR-based genome editing.
• Focused on potentially curative therapeutics.

Negative

• None.

CAMBRIDGE, Mass., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, will present its fourth quarter and full-year 2022 financial results and operational highlights in a conference call on February 23, 2023, at 8 a.m. ET.

To join the call:

• U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call. All participants should ask to be connected to the Intellia Therapeutics conference call.
• Please visit this link for a simultaneous live webcast of the call.

A replay of the call will be available through the Events and Presentations page of the Investors & Media section on Intellia’s website at www.intelliatx.com, beginning on February 23, 2023, at 12 p.m. ET.

About Intellia Therapeutics

Intellia Therapeutics, a leading clinical-stage genome editing company, is developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. To fully realize the transformative potential of CRISPR-based technologies, Intellia is pursuing two primary approaches. The company’s in vivo programs use intravenously administered CRISPR as the therapy, in which proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia’s ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases. Intellia’s deep scientific, technical and clinical development experience, along with its robust intellectual property portfolio, have enabled the company to take a leadership role in harnessing the full potential of genome editing to create new classes of genetic medicine. Learn more at intelliatx.com. Follow us on Twitter @intelliatx.

Intellia Contacts:

Investors:
Ian Karp
Senior Vice President, Investor Relations and Corporate Communications
+1-857-449-4175
ian.karp@intelliatx.com

Lina Li
Senior Director, Investor Relations and Corporate Communications
+1-857-706-1612
lina.li@intelliatx.com

FAQ

When will Intellia Therapeutics announce its Q4 2022 financial results?

Intellia Therapeutics will announce its Q4 2022 financial results on February 23, 2023, at 8 a.m. ET.

How can I join the Intellia Therapeutics conference call?

To join the call, U.S. callers should dial 1-833-316-0545, and international callers should dial 1-412-317-5726.

What technologies does Intellia Therapeutics use for its therapeutics?

Intellia Therapeutics leverages CRISPR-based technologies for developing novel therapeutics.

Where can I find the replay of the Intellia conference call?

The replay of the conference call will be available on Intellia's Investors & Media section starting February 23, 2023, at 12 p.m. ET.